Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer, inflammatory and autoimmune diseases. The company's pipeline was licensed from the Spanish National Cancer Research Centre (CNIO). IBL-101 is a pan-PIM kinase inhibitor in development for autoimmune and inflammatory disease. IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for B-cell malignancies, AML and multiple myeloma. The partnered pipeline comprises AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences. For more information please visit www.inflectionbio.com Inflection Biosciences Ltd总部位于都柏林和伦敦，正在开发小分子癌症治疗药物。公司的创新抗癌药产品线授权来自西班牙国立癌症研究中心(CNIO)。该产品线包括IBL-300系列（PIM/PI3K/mTOR抑制剂），选自一系列独特的双机制激酶抑制剂的IBL-202（PIM/PI3K抑制剂），以及IBL-100系列（选择性泛PIM激酶抑制剂），目前在临床前期开发阶段。现有的数据显示产品对一系列难治性实体肿瘤和血液学恶性肿瘤有潜在的应用。Inflection Biosciences在14年被爱尔兰制药奖评为年度最佳初创企业。 欲了解进一步信息，请访问www.inflectionbio.com。